Why a CXCR4 PET/CT tracer could become Pentixapharm’s most important cardiovascular asset
See why Pentixapharm’s Phase 3 CXCR4 PET/CT push could challenge a stubborn diagnostic bottleneck in primary aldosteronism.
![Representative image: A PET/CT imaging suite illustrates how Pentixapharm’s [68Ga]Ga-PentixaFor Phase 3 PANDA study could reshape primary aldosteronism diagnostics and cardiovascular precision medicine.](https://pharmadevicenews.com/wp-content/uploads/2026/06/Pentixapharms-FDA-clearance-puts-CXCR4-PET-CT-into-a-higher-stakes-diagnostic-race-e1780989931457.webp)
Medical Devices & Diagnostics